- Founded
- 2009
- Stage
- Seed-2
- Invested
- 2018
- Status
- Private
Medikine utilizes a proprietary platform to identify agonists of clinically relevant heterodimeric cytokine receptors for the development of novel therapeutics for immuno-oncology applications in cell therapy and neo-antigen vaccines.